Search
Organogenesis Holdings Inc
ORGOAdd to Watchlist
2.360USD
-0.080-3.28%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
303.67MMarket Cap
LossP/E TTM
More Details of Organogenesis Holdings Inc Company
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Organogenesis Holdings Inc Info
Ticker SymbolORGO
Company nameOrganogenesis Holdings Inc
IPO dateDec 02, 2016
CEOGillheeney (Gary S)
Number of employees869
Security typeOrdinary Share
Fiscal year-endDec 02
Address85 Dan Rd
CityCANTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02021-2810
Phone17815750775
Websitehttps://investors.organogenesis.com
Ticker SymbolORGO
IPO dateDec 02, 2016
CEOGillheeney (Gary S)
Company Executives of Organogenesis Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Glenn H. Nussdorf
Mr. Glenn H. Nussdorf
Director
Director
12.25M
+4.08%
Mr. Patrick Bilbo
Mr. Patrick Bilbo
Chief Operating Officer
Chief Operating Officer
603.77K
-3.81%
Mrs. Lori Freedman, J.D.
Mrs. Lori Freedman, J.D.
Chief Administrative and Legal Officer
Chief Administrative and Legal Officer
552.73K
-7.99%
Mr. Brian Grow
Mr. Brian Grow
Chief Commercial Officer
Chief Commercial Officer
369.52K
-16.30%
Mr. Robert Cavorsi
Mr. Robert Cavorsi
Vice President - Strategy
Vice President - Strategy
275.52K
-0.25%
Mr. Arthur S. Leibowitz, CPA
Mr. Arthur S. Leibowitz, CPA
Lead Independent Director
Lead Independent Director
242.19K
+0.31%
Mr. Antonio S. Montecalvo
Mr. Antonio S. Montecalvo
Vice President - Health Policy
Vice President - Health Policy
217.76K
+13.57%
Ms. Prathyusha Duraibabu, CPA
Ms. Prathyusha Duraibabu, CPA
Independent Director
Independent Director
198.22K
+0.38%
Mr. Jon L. Giacomin
Mr. Jon L. Giacomin
Independent Director
Independent Director
192.20K
+0.39%
Dr. Gilberto Quintero, Ph.D.
Dr. Gilberto Quintero, Ph.D.
Independent Director
Independent Director
190.25K
+0.39%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Glenn H. Nussdorf
Mr. Glenn H. Nussdorf
Director
Director
12.25M
+4.08%
Mr. Patrick Bilbo
Mr. Patrick Bilbo
Chief Operating Officer
Chief Operating Officer
603.77K
-3.81%
Mrs. Lori Freedman, J.D.
Mrs. Lori Freedman, J.D.
Chief Administrative and Legal Officer
Chief Administrative and Legal Officer
552.73K
-7.99%
Mr. Brian Grow
Mr. Brian Grow
Chief Commercial Officer
Chief Commercial Officer
369.52K
-16.30%
Mr. Robert Cavorsi
Mr. Robert Cavorsi
Vice President - Strategy
Vice President - Strategy
275.52K
-0.25%
Mr. Arthur S. Leibowitz, CPA
Mr. Arthur S. Leibowitz, CPA
Lead Independent Director
Lead Independent Director
242.19K
+0.31%
FAQs
Who are the top five shareholders of Organogenesis Holdings Inc?
The top five shareholders of Organogenesis Holdings Inc are: Mr. Glenn H. Nussdorf
How many institutions hold shares of Organogenesis Holdings Inc (ORGO)?
As of 2026Q1, 303 institutions hold shares of Organogenesis Holdings Inc, with a combined market value of approximately 70.97M, accounting for 55.15% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5515577.00.
What is the biggest source of revenue for Organogenesis Holdings Inc?
In 2026Q1, the Advanced Wound Care business generated the highest revenue for Organogenesis Holdings Inc, amounting to 531.24M and accounting for 94.35% of total revenue.